Sabrina McCrear

Minhee Kang, PharmD, explains how oncology pharmacists translate clinical research into safe, coordinated cancer care.

Minhee Kang, PharmD, discusses 3 key considerations for oncology pharmacists to improve treatment safety, patient education, and care delivery.

NCCN added pemivibart to its lymphoma guidelines, expanding COVID-19 prevention options for immunocompromised patients.

House lawmakers reviewed veterans' health bills focused on mental health, rural access, spinal injury care, and military aviation research.

The House passed HR 5347 to extend flexible Medicare ACO quality reporting and support smaller practices transitioning to digital measures.

Mohit Narang, MD, discusses how community oncology practices can expand access to CAR T and bispecific therapies through better infrastructure and collaboration.

New wastewater data and prior research suggest COVID-19 may follow recurring spring and summer transmission patterns, unlike influenza and RSV.

National HIV Testing Day highlights how state policies, pharmacists, and long-acting therapies are reshaping access to HIV testing, PrEP, and PEP.

Asthma biologics were associated with sustained reductions in exacerbations after 2015 across demographic and clinical subgroups in a large cohort study.

Joseph K. Han, MD, discusses upstream biologics, verekitug, and the future of chronic rhinosinusitis with nasal polyps treatment.

Patients with familial pulmonary fibrosis had faster FVC decline and were more likely to have a UIP pattern, supporting family history as a prognostic tool.

Joseph K. Han, MD, discusses verekitug, unmet needs in CRSwNP, and why better biologic therapies remain necessary.

Peter Hotez, MD, discusses which patients may benefit most from newly approved oral COVID-19 postexposure prophylaxis.

FDA approved Rextovy, a 4-mg OTC naloxone nasal spray, expanding access to opioid overdose reversal medications nationwide.

Pooled TETON trial data showed inhaled treprostinil preserved lung function in IPF, supporting an FDA submission planned for 2026.

A new tudy finds 2024-2025 COVID-19 vaccines reduced hospitalization and critical illness risk among adults, although protection waned over time.

Broader cancer care networks were not consistently associated with lower Medicare Advantage disenrollment after cancer diagnosis.

Distrust, misinformation, and conflict complicate Ebola response efforts in the DRC, highlighting broader challenges to public health trust.

CHMP issued a positive opinion for nerandomilast in IPF and PPF, bringing the therapy closer to European Union approval.

The approval of a new oral postexposure prophylaxis for COVID-19 marks a significant advancement in the disease's prevention landscape.

Phase 3 SUNRISE data show tezepelumab reduced oral corticosteroid use while maintaining asthma control in severe asthma.

Invited commentaries on the CORAL trial praise nalbuphine's potential in IPF cough while raising questions about safety and durability.

Learn how the Cicada COVID-19 variant spreads, common symptoms, who may be at risk, and what precautions experts recommend.

As quarantined cruise passengers return home, experts explain Andes hantavirus symptoms, transmission risks, and prevention.

New CMS Medicaid work requirements could increase employment but may also cause millions of adults to lose coverage by 2027.

Abortion costs and Medicaid coverage vary by state, creating financial barriers for patients seeking care after the Dobbs v Jackson decision.

FDA approves ensitrelvir for COVID-19 postexposure prophylaxis following phase 3 data showing efficacy against Omicron symptoms.

Twice-yearly depemokimab reduced exacerbations and improved quality-of-life outcomes in type 2 asthma and CRSwNP studies.

Medicare FFS beneficiaries with metastatic cancer received broad genomic profiling more often than MA patients.

The Ugandan MInistry of Health closed their border with the DRC in response to the rise in Bundibugyo cases and deaths.